6KTS

Structure of C34N126K/N36

Summary for 6KTS

• Entry DOI: 10.2210/pdb6kts/pdb
• Descriptor: Envelope glycoprotein, Glycoprotein 41 (3 entities in total)
• Functional Keywords: hiv, envlope, 6hb, viral protein
• Biological source: Human immunodeficiency virus 1; More
• Total number of polymer chains: 6
• Total formula weight: 25336.60

Authors

Yu, D.W.,Qin, B. (deposition date: 2019-08-28, release date: 2020-09-16, Last modification date: 2024-10-30)

Primary citation

Yu, D.,Su, Y.,Ding, X.,Zhu, Y.,Qin, B.,Chong, H.,Cui, S.,He, Y.
Structural and Functional Characterization of the Secondary Mutation N126K Selected by Various HIV-1 Fusion Inhibitors.
Viruses, 12:-, 2020

PubMed Abstract: Peptides derived from the C-terminal heptad repeat (CHR) region of HIV-1 gp41 is potent viral membrane fusion inhibitors, such as the first clinically approved peptide drug T20 and a group of newly-designed peptides. The resistance profiles of various HIV-1 fusion inhibitors were previously characterized, and the secondary mutation N126K in the gp41 CHR was routinely identified during the in vitro and in vivo selections. In this study, the functional and structural relevance of the N126K mutation has been characterized from multiple angles. First, we show that a single N126K mutation across several HIV-1 isolates conferred mild to moderate cross-resistances. Second, the N126K mutation exerted different effects on Env-mediated HIV-1 entry and cell-cell fusion. Third, the N126K mutation did not interfere with the expression and processing of viral Env glycoproteins, but it disrupted the Asn126-based glycosylation site in gp41. Fourth, the N126K mutation was verified to enhance the thermal stability of 6-HB conformation. Fifth, we determined the crystal structure of a 6-HB bearing the N126K mutation, which revealed the interhelical and intrahelical interactions underlying the increased thermostability. Therefore, our data provide new information to understand the mechanism of HIV-1 gp41-mediated cell fusion and its resistance mode to viral fusion inhibitors.

PubMed: 32197300
DOI: 10.3390/v12030326

Experimental method

X-RAY DIFFRACTION (1.65 Å)